CEO Gregory Flesher (Reneo)
December 9, 2020 08:39 AM ESTUpdated 01:49 PM
Financing

No­vo and Abing­worth back a $95M Se­ries B for Re­neo Phar­ma­ceu­ti­cals, which aims to treat dis­eases of the mi­to­chon­dria

Max Gelman

Senior Editor

Less than two years af­ter its com­ing-out par­ty with a $50 mil­lion launch round, Re­neo Phar­ma­ceu­ti­cals re­turned to the ven­ture well and reeled in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Biotech VC firm out­lines plans for $100M fund

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

Gilead­'s Kite un­cou­ples from Fo­s­un in Chi­na as Yescar­ta faces cov­er­age ob­sta­cles

A VC-backed ge­net­ic test­ing start­up to 'con­sid­er' mak­ing an of­fer to buy 23andMe

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times